A multicentre, randomised, double-blind, controlled, parallel group study to evaulate the efficacy and safety of different concentrations of FK778 with tacrolimus (FK506) and steroids versus a standard regimen of tacrolimus, MMF [mycophenolate mofetil] and steroids in renal transplant patients

Trial Profile

A multicentre, randomised, double-blind, controlled, parallel group study to evaulate the efficacy and safety of different concentrations of FK778 with tacrolimus (FK506) and steroids versus a standard regimen of tacrolimus, MMF [mycophenolate mofetil] and steroids in renal transplant patients

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Jun 2014

At a glance

  • Drugs FK 778 (Primary) ; Corticosteroids; Mycophenolate mofetil; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 09 Mar 2010 Additional lead trial investigator [Neumayer HH] identified as reported by ClinicalTrials.gov.
    • 05 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top